SURMOUNT-2 (Obesity with T2D) Perhaps the most anticipated trial in the program, SURPASS-2 was a 40-week, head-to-head study comparing Tirzepatide (5, 10, and 15 mg) to the highest approved dose of the potent selective GLP-1 RA, semaglutide (1 mg), in 1,878 patients with T2D on a background of metformin
Diabetologia1986 Jan;29(1):46-52
IMPORTANT NOTE Services included in your enrollment package are intended to be used during your active 12-week program period and do not roll over to future enrollment cycles
[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Bose AK, Mocanu MM, Carr RD et al
Clinical, Cosmetic and Investigational Dermatology, October 2014, pages 267 Do you want more skincare advice, tips and exclusive offers
Two days early on a weekly schedule means a 5-day (120-hour) interval between doses